Vaccine Manufacture and Supply – News and Features

GlobalEnglish Corporation announced that it has been selected to support the global Business English communication needs of Novartis employees.

Human serum albumin from transgenic rice could ease shortages of donated blood.

Novel technologies have boosted the vaccines industry worldwide. Recent technological advances in vaccine research, indicate a promising future for the new generation of vaccines.

CEVEC announces closing of €6M financing round.

The meeting welcomes world class biotechs and pharmas to discuss the opportunities of development of novel vaccine R&D and manufacturing technologies in China.

The Phase I/II, two cohort, open label clinical trial in metastatic melanoma opens at Washington University, St. Louis, Missouri.

Trial could generate future alternative treatment for multiple myeloma.

Eden Biodesign Ltd. today announced the execution of a non-exclusive Vendor Network Agreement with Crucell, under which Eden Biodesign has become a pre-approved authorized provider of process development and cGMP manufacturing services using Crucell’s proprietary PER.C6® cell line technology. Under the terms of the agreement Eden Biodesign will be able to offer its services to Crucell’s PER.C6® licensees in the field of vaccines and gene therapy.

IDT, a global integrated contract manufacturer of vaccines and biopharmaceuticals, has introduced plans to expand its Vaccine Capacity and Workforce.

CEVEC Pharmaceuticals has announced that CAP cells produce high virus titers upon infection with influenza strains.